Super Generics – The Next Step For Generic Players As Commoditized Drugs Yield Less Margins – DIA India Conference
This article was originally published in PharmAsia News
It takes tremendous efforts but generic companies eye complex drugs for lasting gains, said DIA India speakers.
You may also be interested in...
MUMBAI - Dr. Reddy's Laboratories Ltd. faced an unexpected slowdown in its home market as sales growth in India slipped to just 6% during the first quarter - remarkably lower than the industry average of 14% to 15% - but a 69% rise in sales of its biosimilars products like monoclonal antibody Reditux (rituximab) powered revenues to a respectable $66 million, against $62 million achieved during the same period last year
Possibly acquiring development expertise in biosimilars from the Swiss firm BioPartners is one of several strategic moves that newly appointed chief executive Claudio Albrecht is now making at the generics company Actavis
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.